Epsilon M&A Deal Report - Zellbios
Transaction Multiples for the Valuation of Private Companies
Private Group led by DPE Deutsche Private Equity / Zellbios
No EMAT :
63146
Announced Date :
16/12/2013
Type :
SBO (Secondary Buy Out) ,Exit
Deal Value :
Yes
Acquirer :
Private Group led by DPE Deutsche Private Equity
Target :
Zellbios
Country :
Luxembourg
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
Business Description :
Founded in 2011 via the merger of the Italian Company Farmabios and the German firm PharmaZell, Zellbios manufactures niche active pharmaceutical ingredients (APIs) , mostly off-patent, for...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
Rating :
*
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
| Date | Acquirer | Target | Country | Multiples | See details |
| 13/03/2014 | Charles River Laboratories International | CRO services division of Galapagos NV (Argenta and BioFocus) | Netherlands | ** | 63103 |
| 06/01/2014 | Henry Schein | Five Arseus companies in Belgium, France and the Netherlands | Belgium | * | 63097 |
Source: Epsilon Research / EMAT
